Planning Alternatives Ltd. ADV Raises Position in Eli Lilly and Company (NYSE:LLY)

Planning Alternatives Ltd. ADV increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 559 shares of the company’s stock after purchasing an additional 16 shares during the period. Planning Alternatives Ltd. ADV’s holdings in Eli Lilly and Company were worth $495,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LLY. Raymond James Trust N.A. boosted its position in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. Raymond James Trust N.A. now owns 34,943 shares of the company’s stock worth $30,957,000 after purchasing an additional 240 shares in the last quarter. Valence8 US LP purchased a new stake in Eli Lilly and Company during the third quarter worth about $561,000. Darden Wealth Group Inc grew its position in Eli Lilly and Company by 3.8% during the third quarter. Darden Wealth Group Inc now owns 1,515 shares of the company’s stock worth $1,342,000 after buying an additional 55 shares during the period. Eagle Asset Management Inc. increased its holdings in Eli Lilly and Company by 33.8% in the third quarter. Eagle Asset Management Inc. now owns 29,394 shares of the company’s stock valued at $24,443,000 after buying an additional 7,425 shares in the last quarter. Finally, HealthInvest Partners AB lifted its position in shares of Eli Lilly and Company by 12.6% during the 3rd quarter. HealthInvest Partners AB now owns 30,564 shares of the company’s stock valued at $27,078,000 after acquiring an additional 3,420 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on LLY shares. Citigroup upped their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Guggenheim lifted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Finally, Sanford C. Bernstein assumed coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,007.94.

Eli Lilly and Company Trading Down 0.6 %

Shares of LLY stock opened at $748.91 on Friday. The firm’s 50-day simple moving average is $868.53 and its 200-day simple moving average is $869.14. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 1-year low of $561.65 and a 1-year high of $972.53. The firm has a market cap of $710.96 billion, a P/E ratio of 80.96, a PEG ratio of 2.76 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. During the same period in the prior year, the business earned $0.10 EPS. The business’s revenue for the quarter was up 20.4% on a year-over-year basis. As a group, equities analysts forecast that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.